Alkermes (ALKS) Stock Forecast & Price Target

Compare

551 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALKS Analyst Ratings

Moderate Buy

9 Buy

4 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Alkermes

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$40.51

▲(25.92% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $40.51 with a high forecast of $54.00 and a low forecast of $26.13. The average price target represents a 25.92% change from the last price of $32.17.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","40":"$40","55":"$55","32.5":"$32.5","47.5":"$47.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,32.5,40,47.5,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.65,32.44615384615385,34.24230769230769,36.03846153846154,37.83461538461538,39.63076923076923,41.426923076923075,43.223076923076924,45.01923076923077,46.815384615384616,48.61153846153846,50.40769230769231,52.20384615384616,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.65,31.408461538461538,32.16692307692308,32.925384615384615,33.683846153846154,34.44230769230769,35.200769230769225,35.95923076923077,36.7176923076923,37.47615384615384,38.23461538461538,38.99307692307692,39.75153846153846,{"y":40.51,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.65,30.30230769230769,29.954615384615384,29.606923076923074,29.25923076923077,28.91153846153846,28.563846153846153,28.216153846153844,27.86846153846154,27.52076923076923,27.173076923076923,26.825384615384614,26.47769230769231,{"y":26.13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$54.00

Average Price Target$40.51

Lowest Price Target$26.13

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leonid Timashev

RBC Capital

$44→$45

Buy

39.88%

Upside

Reiterated

10/08/25

RBC Capital Reaffirms Their Buy Rating on Alkermes (ALKS)RBC Capital analyst Leonid Timashev raised the price target on Alkermes (NASDAQ: ALKS) to $45.00 (from $44.00) while maintaining a Outperform rating.

Uy Ear

Mizuho Securities

$40

Buy

24.34%

Upside

Reiterated

10/08/25

Mizuho Securities Remains a Buy on Alkermes (ALKS)

Marc Goodman

Leerink Partners

―

Hold

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Hold Rating for Alkermes (ALKS)

David Amsellem

Piper Sandler

$38

Buy

18.12%

Upside

Reiterated

10/06/25

Piper Sandler Reaffirms Their Buy Rating on Alkermes (ALKS)

Benjamin Burnett

Wells Fargo

$30→$44

Buy

36.77%

Upside

Reiterated

10/01/25

Wells Fargo Sticks to Its Buy Rating for Alkermes (ALKS)Equity ResearchAlkermes PLC (ALKS) | Biotechnology | Ben Burnett | Overweight | PT $44 (47% Upside)

Paul Matteis

Stifel Nicolaus

$42

Buy

30.56%

Upside

Reiterated

09/30/25

Alkermes (ALKS) Receives a Buy from Stifel NicolausWe are reiterating our Buy rating on ALKS.

Douglas Tsao

H.C. Wainwright

$46

Hold

42.99%

Upside

Reiterated

09/09/25

Alkermes Hold Rating: Promising NT1 Data Amidst Competitive and Clinical Challenges

Jessica Fye

J.P. Morgan

$34→$35

Hold

8.80%

Upside

Reiterated

09/09/25

J.P. Morgan Sticks to Its Hold Rating for Alkermes (ALKS)Raising our YE25 price target to $35 from prior $34.

Joseph Thome

TD Cowen

$38

Buy

18.12%

Upside

Reiterated

09/08/25

TD Cowen Remains a Buy on Alkermes (ALKS)

Jason Gerberry

Bank of America Securities

$33

Hold

2.58%

Upside

Reiterated

09/08/25

Cautious Hold Rating on Alkermes Amid Competitive Pressures and Mixed Data for ALKS2680

Ami Fadia

Needham

$45

Buy

39.88%

Upside

Reiterated

07/29/25

Alkermes' Strong Q2 2025 Performance and Future Growth Potential Justify Buy Rating

Akash Tewari

Jefferies

$50→$54

Buy

67.86%

Upside

Reiterated

07/22/25

Alkermes price target raised to $54 from $50 at JefferiesAlkermes price target raised to $54 from $50 at Jefferies

Andrea Newkirk

Goldman Sachs

$26.13

Buy

-18.78%

Downside

Initiated

07/15/25

Alkermes: Promising Growth with Established Neuropsychological Portfolio and Emerging Orexin Agonist Opportunities

Ashwani Verma

UBS

$33→$42

Buy

30.56%

Upside

Upgraded

06/17/25

Analysts Conflicted on These Healthcare Names: Roche Holding AG (Other OTC: RHHVF) and Alkermes (NASDAQ: ALKS)

Charles Duncan

Cantor Fitzgerald

$43

Buy

33.66%

Upside

Reiterated

05/11/25

Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leonid Timashev

RBC Capital

$44→$45

Buy

39.88%

Upside

Reiterated

10/08/25

Uy Ear

Mizuho Securities

$40

Buy

24.34%

Upside

Reiterated

10/08/25

Mizuho Securities Remains a Buy on Alkermes (ALKS)

Marc Goodman

Leerink Partners

―

Hold

―

Reiterated

10/07/25

Leerink Partners Sticks to Its Hold Rating for Alkermes (ALKS)

David Amsellem

Piper Sandler

$38

Buy

18.12%

Upside

Reiterated

10/06/25

Piper Sandler Reaffirms Their Buy Rating on Alkermes (ALKS)

Benjamin Burnett

Wells Fargo

$30→$44

Buy

36.77%

Upside

Reiterated

10/01/25

Wells Fargo Sticks to Its Buy Rating for Alkermes (ALKS)Equity ResearchAlkermes PLC (ALKS) | Biotechnology | Ben Burnett | Overweight | PT $44 (47% Upside)

Paul Matteis

Stifel Nicolaus

$42

Buy

30.56%

Upside

Reiterated

09/30/25

Alkermes (ALKS) Receives a Buy from Stifel NicolausWe are reiterating our Buy rating on ALKS.

Douglas Tsao

H.C. Wainwright

$46

Hold

42.99%

Upside

Reiterated

09/09/25

Alkermes Hold Rating: Promising NT1 Data Amidst Competitive and Clinical Challenges

Jessica Fye

J.P. Morgan

$34→$35

Hold

8.80%

Upside

Reiterated

09/09/25

J.P. Morgan Sticks to Its Hold Rating for Alkermes (ALKS)Raising our YE25 price target to $35 from prior $34.

Joseph Thome

TD Cowen

$38

Buy

18.12%

Upside

Reiterated

09/08/25

TD Cowen Remains a Buy on Alkermes (ALKS)

Jason Gerberry

Bank of America Securities

$33

Hold

2.58%

Upside

Reiterated

09/08/25

Cautious Hold Rating on Alkermes Amid Competitive Pressures and Mixed Data for ALKS2680

Ami Fadia

Needham

$45

Buy

39.88%

Upside

Reiterated

07/29/25

Alkermes' Strong Q2 2025 Performance and Future Growth Potential Justify Buy Rating

Akash Tewari

Jefferies

$50→$54

Buy

67.86%

Upside

Reiterated

07/22/25

Alkermes price target raised to $54 from $50 at JefferiesAlkermes price target raised to $54 from $50 at Jefferies

Andrea Newkirk

Goldman Sachs

$26.13

Buy

-18.78%

Downside

Initiated

07/15/25

Alkermes: Promising Growth with Established Neuropsychological Portfolio and Emerging Orexin Agonist Opportunities

Ashwani Verma

UBS

$33→$42

Buy

30.56%

Upside

Upgraded

06/17/25

Analysts Conflicted on These Healthcare Names: Roche Holding AG (Other OTC: RHHVF) and Alkermes (NASDAQ: ALKS)

Charles Duncan

Cantor Fitzgerald

$43

Buy

33.66%

Upside

Reiterated

05/11/25

Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

1 Month

xxx

Success Rate

11/18 ratings generated profit

Average Return

+4.32%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.11% of your transactions generating a profit, with an average return of +4.32% per trade.

3 Months

xxx

Success Rate

14/18 ratings generated profit

Average Return

+7.37%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +7.37% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

17/18 ratings generated profit

Average Return

+21.66%

reiterated a buy rating 15 days ago

Copying Paul Matteis's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +21.66% per trade.

2 Years

xxx

Success Rate

22/22 ratings generated profit

Average Return

+15.83%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +15.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALKS has received 20 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ALKS average Analyst price target in the past 3 months is 40.51.

Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Next quarter’s earnings estimate for ALKS is $0.38 with a range of $0.29 to $0.53. The previous quarter’s EPS was $0.67. ALKS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ALKS has Preformed in-line its overall industry.

ALKS Sales Forecast

Next quarter’s sales forecast for ALKS is $355.64M with a range of $340.54M to $370.09M. The previous quarter’s sales results were $390.66M. ALKS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ALKS has Preformed in-line its overall industry.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?

Based on analyst ratings, Alkermes’s 12-month average price target is 40.51.

What is ALKS’s upside potential, based on the analysts’ average price target?

Alkermes has 25.92% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALKS a Buy, Sell or Hold?

Alkermes has a consensus rating of Moderate Buy which is based on 9 buy ratings, 4 hold ratings and 0 sell ratings.

What is Alkermes’s price target?

The average price target for Alkermes is 40.51. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $54.00 ,the lowest forecast is $26.13. The average price target represents 25.92% Increase from the current price of $32.17.

What do analysts say about Alkermes?

Alkermes’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of ALKS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Alkermes (ALKS) Stock Forecast & Price Target

ALKS Analyst Ratings

ALKS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alkermes

ALKS Analyst Recommendation Trends

ALKS Financial Forecast

ALKS Earnings Forecast

ALKS Sales Forecast

ALKS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts